{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:42:29Z","timestamp":1792417349662,"version":"4.4.0"},"reference-count":66,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Peripheral immune alterations are widely reported in Parkinson\u2019s disease (PD), but their biological meaning and clinical utility remain uncertain because circulating immune profiles are shaped by aging, latent infection, medication exposure, comorbidity, disease stage, and preanalytical conditions. This concept-driven narrative review examines how technically valid peripheral immune findings should be biologically interpreted and clinically qualified through an immune-context phenotyping framework. Available human evidence suggests alterations in neutrophil- and monocyte-related inflammatory indices and cellular states, \u03b1-synuclein\u2013responsive T-cell pathways, cytotoxic and regulatory T-cell states, B-cell phenotypic alterations, and peripheral\u2013central immune associations. Much of this evidence, however, derives from cross-sectional and cohort-dependent studies, and within the human evidence considered in this review, PD specificity remains insufficiently established for most candidate signals. An observed blood difference may reflect altered production, survival, differentiation, redistribution, denominator effects, systemic inflammatory context, or measurement-related distortion rather than a single disease mechanism. Immune-context phenotyping, therefore, integrates trait, state, disease-trajectory, measurement, and treatment contexts with biological identifiability, disease-control comparisons, cross-compartment corroboration, repeated sampling, and external validation. The framework adapts established biomarker concepts to distinguish diagnostic, prognostic, monitoring, predictive, pharmacodynamic\/response, and treatment-selection claims without treating peripheral target engagement, CNS engagement, pathway modification, and clinical benefit as equivalent. Based on the human evidence considered in this review, no peripheral immune phenotype appears ready for stand-alone clinical implementation in PD. The proposed framework defines a testable path from descriptive peripheral immune associations toward biologically coherent, temporally informative, and clinically qualified phenotypes.<\/jats:p>","DOI":"10.1515\/revneuro-2026-0155","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:55:55Z","timestamp":1792414555000},"source":"Crossref","is-referenced-by-count":0,"title":["Interpreting peripheral immune phenotypes in Parkinson\u2019s disease: an immune-context framework for biomarker qualification"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9003-5781","authenticated-orcid":false,"given":"Osman","family":"Kahveci","sequence":"first","affiliation":[{"name":"Department of Physiology, Faculty of Medicine , Bezmialem Vak\u0131f University , Topkap\u0131 Mahallesi, Adnan Menderes Bulvar\u0131 No: 113, 34093 Fatih , Istanbul , T\u00fcrkiye"},{"name":"Department of Physiology, Istanbul Faculty of Medicine , Istanbul University , Topkap\u0131 Mahallesi, Turgut \u00d6zal Caddesi No: 118, 34093 Fatih , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-3681","authenticated-orcid":false,"given":"Ula\u015f","family":"Ay","sequence":"additional","affiliation":[{"name":"Department of Physiology, Istanbul Faculty of Medicine , Istanbul University , Topkap\u0131 Mahallesi, Turgut \u00d6zal Caddesi No: 118, 34093 Fatih , Istanbul , T\u00fcrkiye"},{"name":"Neuroimaging Unit, Hulusi Beh\u00e7et Life Sciences Research Laboratory , Istanbul University , Topkap\u0131 Mahallesi, Turgut \u00d6zal Caddesi No: 118, 34093 Fatih , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2908-8475","authenticated-orcid":false,"given":"Hakan","family":"G\u00fcrvit","sequence":"additional","affiliation":[{"name":"Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine , Istanbul University , Topkap\u0131 Mahallesi, Turgut \u00d6zal Caddesi No: 118, 34093 Fatih , Istanbul , T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026101912554602075_j_revneuro-2026-0155_ref_001","doi-asserted-by":"crossref","unstructured":"Al-Bachari, S., Naish, J.H., Parker, G.J.M., Emsley, H.C.A., and Parkes, L.M. (2020). Blood\u2013brain barrier leakage is increased in Parkinson\u2019s disease. Front. Physiol. 11: 593026, https:\/\/doi.org\/10.3389\/fphys.2020.593026.","DOI":"10.3389\/fphys.2020.593026"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_002","doi-asserted-by":"crossref","unstructured":"Borghammer, P. and Van Den Berge, N. (2019). Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J.\u00a0Parkinsons Dis. 9: S281\u2013S295, https:\/\/doi.org\/10.3233\/jpd-191721.","DOI":"10.3233\/JPD-191721"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_003","doi-asserted-by":"crossref","unstructured":"Bovenzi, R., Conti, M., Simonetta, C., Bissacco, J., Mascioli, D., Mancini, M., Buttarazzi, V., Veltri, F., Sancesario, G.M., Bagetta, S., et al.. (2025). Sex-specific immune-biological profiles in Parkinson\u2019s disease. J.\u00a0Neuroimmunol. 403: 578610, https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578610.","DOI":"10.1016\/j.jneuroim.2025.578610"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_004","doi-asserted-by":"crossref","unstructured":"Braak, H., Del Tredici, K., R\u00fcb, U., de Vos, R.A.I., Jansen Steur, E.N.H., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24: 197\u2013211, https:\/\/doi.org\/10.1016\/s0197-4580(02)00065-9.","DOI":"10.1016\/S0197-4580(02)00065-9"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_005","doi-asserted-by":"crossref","unstructured":"Braak, H., de Vos, R.A.I., Bohl, J., and Del Tredici, K. (2006). Gastric \u03b1-synuclein immunoreactive inclusions in Meissner\u2019s and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology. Neurosci. Lett. 396: 67\u201372, https:\/\/doi.org\/10.1016\/j.neulet.2005.11.012.","DOI":"10.1016\/j.neulet.2005.11.012"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_006","doi-asserted-by":"crossref","unstructured":"Capelle, C.M., Cir\u00e9, S., Hedin, F., Hansen, M., Pavelka, L., Grzyb, K., Kyriakis, D., Hunewald, O., Konstantinou, M., Revets, D., et al.. (2023). Early-to-mid stage idiopathic Parkinson\u2019s disease shows enhanced cytotoxicity and differentiation in CD8\u00a0T-cells in females. Nat. Commun. 14: 7461, https:\/\/doi.org\/10.1038\/s41467-023-43053-0.","DOI":"10.1038\/s41467-023-43053-0"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_007","doi-asserted-by":"crossref","unstructured":"Chen, Z., Xie, L., Jin, Q., and Shi, M. (2026). Peripheral inflammation predicts motor, cognitive, and disease progression in Parkinson\u2019s disease: a 4-year longitudinal study from the PPMI cohorts. Neurol. Sci. 47: 388, https:\/\/doi.org\/10.1007\/s10072-026-09002-7.","DOI":"10.1007\/s10072-026-09002-7"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_008","doi-asserted-by":"crossref","unstructured":"Cheng, Y.-K. and Chiang, H.-S. (2025). The interrelationship between intestinal immune cells and enteric \u03b1-synuclein in the progression of Parkinson\u2019s disease. Neurol. Sci. 46: 2965\u20132977, https:\/\/doi.org\/10.1007\/s10072-025-08114-w.","DOI":"10.1007\/s10072-025-08114-w"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_009","doi-asserted-by":"crossref","unstructured":"de Castro Fonseca, M., Zanetti, L., Fanourakis, S., Sulzer, D.L., and Mazmanian, S.K. (2026). The gut microbiome, systemic inflammation, and autoimmunity in Parkinson\u2019s disease. Lancet Neurol. 25: 103\u2013114, https:\/\/doi.org\/10.1016\/s1474-4422(25)00382-5.","DOI":"10.1016\/S1474-4422(25)00382-5"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_010","doi-asserted-by":"crossref","unstructured":"Espinosa-C\u00e1rdenas, R., Arce-Sillas, A., \u00c1lvarez-Luquin, D., Leyva-Hern\u00e1ndez, J., Montes-Moratilla, E., Gonz\u00e1lez-Saavedra, I., Boll, M.C., Garcia-Garcia, E., \u00c1ngeles-Perea, S., Fragoso, G., et al.. (2020). Immunomodulatory effect and clinical outcome in Parkinson\u2019s disease patients on levodopa-pramipexole combo therapy: a two-year prospective study. J.\u00a0Neuroimmunol. 347: 577328, https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577328.","DOI":"10.1016\/j.jneuroim.2020.577328"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_011","doi-asserted-by":"crossref","unstructured":"Farmen, K., Nissen, S.K., Stokholm, M.G., Iranzo, A., \u00d8stergaard, K., Serradell, M., Otto, M., Svendsen, K.B., Garrido, A., Vilas, D., et al.. (2021). Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc. Natl. Acad. Sci. USA 118: e2020858118, https:\/\/doi.org\/10.1073\/pnas.2020858118.","DOI":"10.1073\/pnas.2020858118"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_012","unstructured":"FDA\u2013NIH Biomarker Working Group (2025). BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US), https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/ (Accessed 7 January 2025)."},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_013","doi-asserted-by":"crossref","unstructured":"Furgiuele, A., Pereira, F.C., Martini, S., Marino, F., and Cosentino, M. (2023). Dopaminergic regulation of inflammation and immunity in Parkinson\u2019s disease: friend or foe? Clin. Transl. Immunology 12: e1469, https:\/\/doi.org\/10.1002\/cti2.1469.","DOI":"10.1002\/cti2.1469"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_014","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2018). Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17: 939\u2013953."},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_015","doi-asserted-by":"crossref","unstructured":"Greenland, J.C., Holbrook, J., Kahanawita, L., Camacho, M., Fryer, T.D., Hong, Y.T., and Williams-Gray, C.H. (2025). Peripheral-central immune crosstalk in Parkinson\u2019s disease and its association with clinical severity. Brain Behav. Immun. 128: 558\u2013570, https:\/\/doi.org\/10.1016\/j.bbi.2025.04.028.","DOI":"10.1016\/j.bbi.2025.04.028"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_016","doi-asserted-by":"crossref","unstructured":"Grillo, P., Sancesario, G.M., Bovenzi, R., Zenuni, H., Bissacco, J., Mascioli, D., Simonetta, C., Forti, P., Degoli, G.R., Pieri, M., et al.. (2023). Neutrophil-to-lymphocyte ratio and lymphocyte count reflect alterations in central neurodegeneration-associated proteins and clinical severity in Parkinson disease patients. Parkinsonism Relat. Disord. 112: 105480, https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105480.","DOI":"10.1016\/j.parkreldis.2023.105480"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_017","doi-asserted-by":"crossref","unstructured":"Grozdanov, V., Bliederhaeuser, C., Ruf, W.P., Roth, V., Fundel-Clemens, K., Zondler, L., Brenner, D., Martin-Villalba, A., Hengerer, B., Kassubek, J., et al.. (2014). Inflammatory dysregulation of blood monocytes in Parkinson\u2019s disease patients. Acta Neuropathol. 128: 651\u2013663, https:\/\/doi.org\/10.1007\/s00401-014-1345-4.","DOI":"10.1007\/s00401-014-1345-4"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_018","doi-asserted-by":"crossref","unstructured":"Hasselbalch, I.C., S\u00f8ndergaard, H.B., Koch-Henriksen, N., Olsson, A., Ullum, H., Sellebjerg, F., and Oturai, A.B. (2018). The neutrophil-to-lymphocyte ratio is associated with multiple sclerosis. Mult. Scler. J.\u00a0Exp. Transl. Clin. 4: 2055217318813183, https:\/\/doi.org\/10.1177\/2055217318813183.","DOI":"10.1177\/2055217318813183"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_019","doi-asserted-by":"crossref","unstructured":"Holbrook, J., Patel, B., Camacho, M., Kahanawita, L., Greenland, J., and Williams-Gray, C.H. (2023). Natural killer cells have an activated profile in early Parkinson\u2019s disease. J.\u00a0Neuroimmunol. 382: 578154, https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578154.","DOI":"10.1016\/j.jneuroim.2023.578154"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_020","doi-asserted-by":"crossref","unstructured":"Horsager, J. and Borghammer, P. (2024). Brain-first versus body-first Parkinson\u2019s disease: an update on recent evidence. Parkinsonism Relat. Disord. 122: 106101, https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106101.","DOI":"10.1016\/j.parkreldis.2024.106101"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_021","doi-asserted-by":"crossref","unstructured":"Hosseini, S., Shafiabadi, N., Khanzadeh, M., Ghaedi, A., Ghorbanzadeh, R., Azarhomayoun, A., Bazrgar, A., Pezeshki, J., Bazrafshan, H., and Khanzadeh, S. (2023). Neutrophil-to-lymphocyte ratio in Parkinson\u2019s disease: a systematic review and meta-analysis. BMC Neurol 23: 333, https:\/\/doi.org\/10.1186\/s12883-023-03380-7.","DOI":"10.1186\/s12883-023-03380-7"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_022","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Huang, H., Chen, Y., Xie, H., Lu, Y., Ge, Y., Yao, R., Wang, L., Wu, Z., Bu, Y., et al.. (2025). The role of the immune system in Parkinson\u2019s disease pathogenesis: a focus on Th17 cells\u2014a systematic review and meta-analysis. J.\u00a0Neuroimmunol. 398: 578484, https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578484.","DOI":"10.1016\/j.jneuroim.2024.578484"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_023","doi-asserted-by":"crossref","unstructured":"Jiang, G.-Y., Li, F., Yin, J.-H., and Cao, L.-X. (2026). Peripheral inflammatory biomarkers in Parkinson\u2019s disease: clinical correlations and stratification. Cell. Mol. Neurobiol. 46: 73, https:\/\/doi.org\/10.1007\/s10571-026-01708-8.","DOI":"10.1007\/s10571-026-01708-8"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_024","doi-asserted-by":"crossref","unstructured":"Johansson, E., Freuchet, A., Williams, G.P., Michealis, T., Frazier, A., Litvan, I., Goldman, J.G., Alcalay, R.N., Standaert, D.G., Amara, A.W., et al.. (2025). T\u00a0cell responses towards PINK1 and \u03b1-synuclein are elevated in prodromal Parkinson\u2019s disease. NPJ Parkinsons Dis. 11: 137, https:\/\/doi.org\/10.1038\/s41531-025-01001-3.","DOI":"10.1038\/s41531-025-01001-3"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_025","doi-asserted-by":"crossref","unstructured":"Kahveci, O., Ay, U., and Demiralp, T. (2026). Striatal dopaminergic reserve shapes the longitudinal impact of peripheral immune activation on motor progression in Parkinson\u2019s disease. Mov. Disord., in press, https:\/\/doi.org\/10.1002\/mds.70549.","DOI":"10.1002\/mds.70549"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_026","doi-asserted-by":"crossref","unstructured":"Kouli, A., Jensen, M., Papastavrou, V., Scott, K.M., Kolenda, C., Parker, C., Solim, I.H., Camacho, M., Martin-Ruiz, C., and Williams-Gray, C.H. (2021). T lymphocyte senescence is attenuated in Parkinson\u2019s disease. J.\u00a0Neuroinflammation 18: 228, https:\/\/doi.org\/10.1186\/s12974-021-02287-9.","DOI":"10.1186\/s12974-021-02287-9"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_027","doi-asserted-by":"crossref","unstructured":"Kumar, R., Geuna, E., Michalarea, V., Guardascione, M., Naumann, U., Lorente, D., Kaye, S.B., and de Bono, J.S. (2015). The neutrophil\u2013lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials. Br. J.\u00a0Cancer 112: 1157\u20131165, https:\/\/doi.org\/10.1038\/bjc.2015.67.","DOI":"10.1038\/bjc.2015.67"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_028","doi-asserted-by":"crossref","unstructured":"Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., et al.. (2018). Parkinson\u2019s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1\/Th2\/T17 and Treg in drug-na\u00efve and drug-treated patients. J.\u00a0Neuroinflammation 15: 205, https:\/\/doi.org\/10.1186\/s12974-018-1248-8.","DOI":"10.1186\/s12974-018-1248-8"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_029","doi-asserted-by":"crossref","unstructured":"Lavisse, S., Goutal, S., Wimberley, C., Tonietto, M., Bottlaender, M., Gervais, P., Kuhnast, B., Peyronneau, M.-A., Barret, O., Lagarde, J., et al.. (2021). Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging. Parkinsonism Relat. Disord. 82: 29\u201336, https:\/\/doi.org\/10.1016\/j.parkreldis.2020.11.011.","DOI":"10.1016\/j.parkreldis.2020.11.011"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_030","doi-asserted-by":"crossref","unstructured":"Lee, J., Kim, H.-J., Nguyen, H.D., Song, S.J., Nguyen Thanh, T., Kwak, I.H., Choi, H.J., Ma, H.-I., and Kim, Y.E. (2026). Differential peripheral NLRP3 inflammasome expression in patients with Parkinson\u2019s disease and patients with multiple system atrophy. J.\u00a0Mov. Disord. 19: 31\u201338, https:\/\/doi.org\/10.14802\/jmd.25124.","DOI":"10.14802\/jmd.25124"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_031","doi-asserted-by":"crossref","unstructured":"Li, R., Tropea, T.F., Baratta, L.R., Zuroff, L., Diaz-Ortiz, M.E., Zhang, B., Shinoda, K., Rezk, A., Alcalay, R.N., Chen-Plotkin, A., et al.. (2022). Abnormal B-cell and Tfh-cell profiles in patients with Parkinson disease: a cross-sectional study. Neurol. Neuroimmunol. Neuroinflamm. 9: e1125, https:\/\/doi.org\/10.1212\/nxi.0000000000001125.","DOI":"10.1212\/NXI.0000000000001125"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_032","doi-asserted-by":"crossref","unstructured":"Li, F., Weng, G., Zhou, H., Zhang, W., Deng, B., Luo, Y., Tao, X., Deng, M., Guo, H., Zhu, S., et al.. (2024). The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and neutrophil-to-high-density-lipoprotein ratio are correlated with the severity of Parkinson\u2019s disease. Front. Neurol. 15: 1322228, https:\/\/doi.org\/10.3389\/fneur.2024.1322228.","DOI":"10.3389\/fneur.2024.1322228"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_034","doi-asserted-by":"crossref","unstructured":"Li, F., Wang, Z., Deng, M., Peng, J., He, G., Tong, Y., Xu, W., Feng, T., and Song, K. (2026). Correlation of systemic immune inflammation index and systemic inflammatory response index with the severity of Parkinson\u2019s disease. Front. Neurol. 17: 1736318, https:\/\/doi.org\/10.3389\/fneur.2026.1736318.","DOI":"10.3389\/fneur.2026.1736318"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_035","doi-asserted-by":"crossref","unstructured":"Lindestam Arlehamn, C.S., Dhanwani, R., Pham, J., Kuan, R., Frazier, A., Rezende Dutra, J., Phillips, E., Mallal, S., Roederer, M., Marder, K.S., et al.. (2020). \u03b1-Synuclein-specific T\u00a0cell reactivity is associated with preclinical and early Parkinson\u2019s disease. Nat. Commun. 11: 1875, https:\/\/doi.org\/10.1038\/s41467-020-15626-w.","DOI":"10.1038\/s41467-020-15626-w"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_036","doi-asserted-by":"crossref","unstructured":"Liu, S.Y., Qiao, H.W., Song, T.B., Liu, X.L., Yao, Y.X., Zhao, C.S., Barret, O., Xu, S.L., Cai, Y.N., Tamagnan, G.D., et al.. (2022). Brain microglia activation and peripheral adaptive immunity in Parkinson\u2019s disease: a multimodal PET study. J.\u00a0Neuroinflammation 19: 209, https:\/\/doi.org\/10.1186\/s12974-022-02574-z.","DOI":"10.1186\/s12974-022-02574-z"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_037","doi-asserted-by":"crossref","unstructured":"Ma, M., Paryani, F., Jakubiak, K., Xia, S., Antoku, S., Kannan, A., Lee, J., Madden, N., Senthil Kumar, S., Li, J., et al.. (2025). The spatial landscape of glial pathology and T\u00a0cell response in Parkinson\u2019s disease substantia nigra. Nat. Commun. 16: 7146, https:\/\/doi.org\/10.1038\/s41467-025-62478-3.","DOI":"10.1038\/s41467-025-62478-3"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_038","doi-asserted-by":"crossref","unstructured":"Magistrelli, L., Storelli, E., Rasini, E., Contaldi, E., Comi, C., Cosentino, M., and Marino, F. (2020). Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson\u2019s disease. Brain Behav. Immun. 89: 668\u2013674, https:\/\/doi.org\/10.1016\/j.bbi.2020.07.005.","DOI":"10.1016\/j.bbi.2020.07.005"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_039","doi-asserted-by":"crossref","unstructured":"Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., Coffey, C.S., Caspell-Garcia, C., Simuni, T., Jennings, D., Tanner, C.M., Trojanowski, J.Q., et al.. (2018). The Parkinson\u2019s Progression Markers Initiative (PPMI): establishing a PD biomarker cohort. Ann. Clin. Transl. Neurol. 5: 1460\u20131477, https:\/\/doi.org\/10.1002\/acn3.644.","DOI":"10.1002\/acn3.644"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_040","doi-asserted-by":"crossref","unstructured":"Mark, J.R., Titus, A.M., Staley, H.A., Alvarez, S., Mahn, S., McFarland, N.R., Wallings, R.L., and Tansey, M.G. (2025). Peripheral immune cell response to stimulation stratifies Parkinson\u2019s disease progression from prodromal to clinical stages. Commun. Biol. 8: 716, https:\/\/doi.org\/10.1038\/s42003-025-08088-7.","DOI":"10.1038\/s42003-025-08088-7"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_041","doi-asserted-by":"crossref","unstructured":"Meglaj Bakra\u010d, S., Mandi\u0107, K., Cvetko Krajinovi\u0107, L., Ma\u010dak \u0160afranko, \u017d., Borove\u010dki, F., Bare\u0161i\u0107, A., and Bla\u017eekovi\u0107, A. (2026). Single-cell analysis of the peripheral immune landscape in Parkinson\u2019s disease: insights into dendritic cell and CD4+ T-cell transcriptomics. NPJ Parkinsons Dis. 12: 73, https:\/\/doi.org\/10.1038\/s41531-026-01283-1.","DOI":"10.1038\/s41531-026-01283-1"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_042","doi-asserted-by":"crossref","unstructured":"Moquin-Beaudry, G., Andriamboavonjy, L., Audet, S., Hamilton, L.K., Duquette, A., Chouinard, S., Panisset, M., and Tetreault, M. (2025). Mapping the peripheral immune landscape of Parkinson\u2019s disease patients with single-cell sequencing. Brain 148: 2847\u20132860, https:\/\/doi.org\/10.1093\/brain\/awaf066.","DOI":"10.1093\/brain\/awaf066"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_043","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Delgado, L., Williams-Gray, C.H., Garraux, G., Clemente, D., \u00d6ztop \u00c7akmak, \u00d6., Greenland, J.C., Figueira, I., Mach\u00edn-D\u00edaz, I., Pirovano, E., di Flora, A., et al.. (2025). Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson\u2019s disease. NPJ Parkinsons Dis. 11: 299, https:\/\/doi.org\/10.1038\/s41531-025-01146-1.","DOI":"10.1038\/s41531-025-01146-1"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_044","doi-asserted-by":"crossref","unstructured":"Nishiwaki, H., Ueyama, J., Ito, M., Hamaguchi, T., Takimoto, K., Maeda, T., Kashihara, K., Tsuboi, Y., Mori, H., Kurokawa, K., et al.. (2024). Meta-analysis of shotgun sequencing of gut microbiota in Parkinson\u2019s disease. npj Parkinsons Dis. 10: 106, https:\/\/doi.org\/10.1038\/s41531-024-00724-z.","DOI":"10.1038\/s41531-024-00724-z"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_045","doi-asserted-by":"crossref","unstructured":"Nissen, S.K., Shrivastava, K., Schulte, C., Otzen, D.E., Goldeck, D., Berg, D., M\u00f8ller, H.J., Maetzler, W., and Romero-Ramos, M. (2019). Alterations in blood monocyte functions in Parkinson\u2019s disease. Mov. Disord. 34: 1711\u20131721, https:\/\/doi.org\/10.1002\/mds.27815.","DOI":"10.1002\/mds.27815"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_046","doi-asserted-by":"crossref","unstructured":"Nissen, S.K., Farmen, K., Carstensen, M., Schulte, C., Goldeck, D., Brockmann, K., and Romero-Ramos, M. (2022). Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson\u2019s disease and cognition. Brain Behav. Immun. 101: 182\u2013193.","DOI":"10.1016\/j.bbi.2022.01.005"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_047","doi-asserted-by":"crossref","unstructured":"Oliver, P.J., Civitelli, L., and Hu, M.T. (2025). The gut\u2013brain axis in early Parkinson\u2019s disease: from prodrome to prevention. J.\u00a0Neurol. 272: 413, https:\/\/doi.org\/10.1007\/s00415-025-13138-5.","DOI":"10.1007\/s00415-025-13138-5"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_048","doi-asserted-by":"crossref","unstructured":"Peng, Y., Kang, X.-H., Yao, S.-Y., Zhang, X., Sugimoto, K., Liu, J., Du, M.-Q., Lin, L.-X., Jiang, D.-Y., Chen, Q., et al.. (2026). Progress of immunotherapies in Parkinson\u2019s disease. CNS Neurosci. Ther. 32: e70964, https:\/\/doi.org\/10.1002\/cns.70964.","DOI":"10.22541\/au.174247947.79344022\/v1"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_049","doi-asserted-by":"crossref","unstructured":"Pike, S.C., Havrda, M., Gilli, F., Zhang, Z., and Salas, L.A. (2024). Immunological shifts during early-stage Parkinson\u2019s disease identified with DNA methylation data on longitudinally collected blood samples. NPJ Parkinsons Dis. 10: 21, https:\/\/doi.org\/10.1038\/s41531-023-00626-6.","DOI":"10.1038\/s41531-023-00626-6"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_050","doi-asserted-by":"crossref","unstructured":"Rajda, C., Dib\u00f3, G., V\u00e9csei, L., and Bergquist, J. (2005). Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson\u2019s disease patients. Neuroimmunomodulation 12: 81\u201384, https:\/\/doi.org\/10.1159\/000083579.","DOI":"10.1159\/000083579"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_051","doi-asserted-by":"crossref","unstructured":"Rajkovaca Latic, I., Popovic, Z., Mijatovic, K., Sahinovic, I., Pekic, V., Vucic, D., Cosic, V., Miskic, B., and Tomic, S. (2024). Association of intestinal inflammation and permeability markers with clinical manifestations of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 123: 106948, https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106948.","DOI":"10.1016\/j.parkreldis.2024.106948"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_052","doi-asserted-by":"crossref","unstructured":"Riboldi, G.M., Vialle, R.A., Navarro, E., Udine, E., de Paiva Lopes, K., Humphrey, J., Allan, A., Parks, M., Henderson, B., Astudillo, K., et al.. (2022). Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson\u2019s disease. Mol. Neurodegener. 17: 52, https:\/\/doi.org\/10.1186\/s13024-022-00554-8.","DOI":"10.1186\/s13024-022-00554-8"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_053","doi-asserted-by":"crossref","unstructured":"Rocha, N.P., Assis, F., Scalzo, P.L., Vieira, \u00c9.L.M., Barbosa, I.G., de Souza, M.S., Christo, P.P., Reis, H.J., and Teixeira, A.L. (2018). Reduced activated T lymphocytes (CD4+CD25+) and plasma levels of cytokines in Parkinson\u2019s disease. Mol. Neurobiol. 55: 1488\u20131497, https:\/\/doi.org\/10.1007\/s12035-017-0404-y.","DOI":"10.1007\/s12035-017-0404-y"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_054","doi-asserted-by":"crossref","unstructured":"Roodveldt, C., Bernardino, L., Oztop-Cakmak, O., Dragic, M., Fladmark, K.E., Ertan, S., Aktas, B., Pita, C., Ciglar, L., Garraux, G., et al.. (2024). The immune system in Parkinson\u2019s disease: what we know so far. Brain 147: 3306\u20133324, https:\/\/doi.org\/10.1093\/brain\/awae177.","DOI":"10.1093\/brain\/awae177"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_055","doi-asserted-by":"crossref","unstructured":"Scott, K.M., Chong, Y.T., Park, S., Wijeyekoon, R.S., Hayat, S., Mathews, R.J., Fitzpatrick, Z., Tyers, P., Wright, G., Whitby, J., et al.. (2023). B lymphocyte responses in Parkinson\u2019s disease and their possible significance in disease progression. Brain Commun. 5: fcad060, https:\/\/doi.org\/10.1093\/braincomms\/fcad060.","DOI":"10.1093\/braincomms\/fcad060"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_056","doi-asserted-by":"crossref","unstructured":"Scott, K.M., Spindler, L.R.B., Peattie, A.R.D., Kouli, A., Fryer, T.D., Hong, Y.T., Camacho, M., Solim, I., Kahanawita, L., and Williams-Gray, C.H. (2025). Multimodal markers of immune activation predict cognitive outcomes in Parkinson\u2019s disease. Brain Behav. Immun. 129: 165\u2013178, https:\/\/doi.org\/10.1016\/j.bbi.2025.05.020.","DOI":"10.1016\/j.bbi.2025.05.020"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_057","doi-asserted-by":"crossref","unstructured":"Sulzer, D., Alcalay, R.N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W.H., Mao, X., et al.. (2017). T\u00a0cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature 546: 656\u2013661, https:\/\/doi.org\/10.1038\/nature22815.","DOI":"10.1038\/nature22815"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_058","doi-asserted-by":"crossref","unstructured":"Tansey, M.G., Wallings, R.L., Houser, M.C., Herrick, M.K., Keating, C.E., and Joers, V. (2022). Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22: 657\u2013673, https:\/\/doi.org\/10.1038\/s41577-022-00684-6.","DOI":"10.1038\/s41577-022-00684-6"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_059","doi-asserted-by":"crossref","unstructured":"Tumpa, J.J., Hayder, Q.U.A., Maisa, N.S., and Islam, M.N. (2025). Peripheral\u2013central immune interactions in Parkinson\u2019s disease: insights into innate and adaptive immunity. Front. Mol. Neurosci. 18: 1682006, https:\/\/doi.org\/10.3389\/fnmol.2025.1682006.","DOI":"10.3389\/fnmol.2025.1682006"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_060","doi-asserted-by":"crossref","unstructured":"Wang, P., Yao, L., Luo, M., Zhou, W., Jin, X., Xu, Z., Yan, S., Li, Y., Xu, C., Cheng, R., et al.. (2021). Single-cell transcriptome and TCR profiling reveal activated and expanded T\u00a0cell populations in Parkinson\u2019s disease. Cell Discov. 7: 52, https:\/\/doi.org\/10.1038\/s41421-021-00280-3.","DOI":"10.1038\/s41421-021-00280-3"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_061","doi-asserted-by":"crossref","unstructured":"Wang, K., Han, K., and Wang, Y. (2026). Antigen-specific adaptive immunity in Parkinson\u2019s disease: peripheral priming, brain-border reactivation and parenchymal injury. J.\u00a0Neuroinflammation 23: 310, https:\/\/doi.org\/10.1186\/s12974-026-03918-9.","DOI":"10.1186\/s12974-026-03918-9"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_062","doi-asserted-by":"crossref","unstructured":"Weber, S., Menees, K.B., Park, J., Agin-Liebes, J., Lin, C.-C., Alcalay, R.N., and Lee, J.-K. (2024). Distinctive CD56dim NK subset profiles and increased NKG2D expression in blood NK cells of Parkinson\u2019s disease patients. NPJ Parkinsons Dis. 10: 36, https:\/\/doi.org\/10.1038\/s41531-024-00652-y.","DOI":"10.1038\/s41531-024-00652-y"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_063","doi-asserted-by":"crossref","unstructured":"Williams, G.P., Freuchet, A., Michaelis, T., Frazier, A., Tran, N.K., Rodrigues Lima-Junior, J., Phillips, E.J., Mallal, S.A., Litvan, I., Goldman, J.G., et al.. (2025). PINK1 is a target of T\u00a0cell responses in Parkinson\u2019s disease. J.\u00a0Clin. Invest. 135: e180478, https:\/\/doi.org\/10.1172\/jci180478.","DOI":"10.1172\/JCI180478"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_064","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Ma, Y., and Shang, H. (2026). Association of neutrophil-to-lymphocyte ratio with incidence and disease progression in Parkinson\u2019s disease. Neuroepidemiology 60: 228\u2013238, https:\/\/doi.org\/10.1159\/000545314.","DOI":"10.1159\/000545314"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_065","doi-asserted-by":"crossref","unstructured":"Xiong, L.L., Du, R.L., Niu, R.Z., Xue, L.L., Chen, L., Huangfu, L.R., Cai, X.X., He, X.Y., Huang, J., Huang, X.Y., et al.. (2024). Single-cell RNA sequencing reveals peripheral immunological features in Parkinson\u2019s disease. NPJ Parkinsons Dis. 10: 185, https:\/\/doi.org\/10.1038\/s41531-024-00790-3.","DOI":"10.1038\/s41531-024-00790-3"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_066","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Xie, X., Cai, Y., Liu, P., Liu, S., Chen, R., Wang, J., Wang, Y., Zhao, Y., Zhu, Z., et al.. (2023). Abnormal immune function of B lymphocyte in peripheral blood of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 116: 105890, https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105890.","DOI":"10.1016\/j.parkreldis.2023.105890"},{"key":"2026101912554602075_j_revneuro-2026-0155_ref_067","doi-asserted-by":"crossref","unstructured":"Zhang, F., Chen, B., Ren, W., Yan, Y., Zheng, X., Jin, S., and Chang, Y. (2024). Association analysis of dopaminergic degeneration and the neutrophil-to-lymphocyte ratio in Parkinson\u2019s disease. Front. Aging Neurosci. 16: 1377994, https:\/\/doi.org\/10.3389\/fnagi.2024.1377994.","DOI":"10.3389\/fnagi.2024.1377994"}],"container-title":["Reviews in the Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0155\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0155\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:57:16Z","timestamp":1792414636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/revneuro-2026-0155\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":66,"alternative-id":["10.1515\/revneuro-2026-0155"],"URL":"https:\/\/doi.org\/10.1515\/revneuro-2026-0155","relation":{},"ISSN":["0334-1763","2191-0200"],"issn-type":[{"value":"0334-1763","type":"print"},{"value":"2191-0200","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}